In vitro selection of HIV-1 TAR variants by the Tat protein

Journal of Biotechnology

Volumn 61, Issue 2, 1998, Pages 117-128

  Marozzi, Anna ^a   Meneveri, Raffaella ^a   Giacca, Mauro ^b   Gutierrez, Maria Ines ^b   Siccardi, Antonio G ^c   Ginelli, Enrico ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Gene therapy; HIV 1; SELEX; TAR; Tat

Indexed keywords

BIOASSAY; MOLECULAR STRUCTURE; NUCLEIC ACID SEQUENCES; PROTEINS; RNA; VIRUSES;

GENE THERAPY;

CLONING;

TRANSACTIVATOR PROTEIN;

ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; RNA SEQUENCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0032522198     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1656(98)00017-0     Document Type: Article

References (37)

1. Baltimore D. Gene therapy: intracellular immunization. Nature. 335:1988;395-396.
2. Barillari G., Buonaguro L., Fiorelli V., Hoffman J., Michaels F., Gallo R.C., Ensoli B. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implication for AIDS-Kaposi's sarcoma pathogenesis. J. Immunol. 149:1992;3727-3734.
3. Bartel D.P., Zapp M.L., Green M.R., Szostak J.K. HIV-1 Rev regulation involves recognition of non-Watson-Crick base pairs in viral RNA. Cell. 67:1991;529-536.
4. Berkhout B., Jeang K.-T. Detailed mutational analysis of TAR RNA: critical spacing between the bulge and loop recognition domains. Nucleic Acids Res. 19:1991;6169-6176.
5. Berkhout B., Klaver B. In vivo selection of randomly mutated retroviral genomes. Nucleic Acids Res. 21:1993;5020-5024.
6. Berkhout B., Klaver B. Revertants and pseudo-revertants of human immunodeficiency virus type 1 viruses mutated in the long terminal repeat region. J. Gen. Virol. 76:1995;845-853.
7. Bohjanen P.R., Colvin R.A., Puttaraju M., Been M.D., Garcia-Blanco M.A. A small circular TAT RNA decoy specifically inhibits Tat-activated HIV-1 transcription. Nucleic Acids Res. 24:1996;3733-3738.
8. Braddock M., Powell R., Sutton J., Kingsman A.J., Kingsman S.M. Orientation-specific cis complementation by bulge- and loop-mutated human immunodeficiency virus type 1 TAR RNA. J. Virol. 68:1994;8396-8400.
9. Carrol R., Peterlin B.M., Derse D. Inhibition of human immunodeficiency virus type 1 Tat activity by coexpression of heterologous trans activators. J. Virol. 66:1992;2000-2007.
10. Cullen B., Green W. Regulatory pathway governing HIV-1 replication. Cell. 58:1989;423-426.
11. Delling U., Reid L.S., Barnett R.W., Ma Y.-X., Climie S., Summer-Smith M., Sonenberg N. Conserved nucleotides in the TAR RNA stem of human immunodeficiency virus type 1 are critical for Tat-binding and trans activation: model for TAR RNA tertiary structure. J. Virol. 66:1992;3018-3025.
12. Demarchi F., d'Adda di Fagnana F., Falaschi A., Giacca M. Activation of transcription factor NF-kB by the Tat protein of human immunodeficiency virus type 1. J. Virol. 70:1996;4427-4437.
13. Dingwall C., Ernberg I., Gait M.J., Green S.M., Heaphy S., Karn J., Lowe A.D., Singh M., Skinner M. HIV-1 tat protein stimulates transcription by binding to the U-rich bulge in the stem of the TAR RNA. EMBO J. 9:1990;4145-4153.
14. Garcia J.A., Gaynor R.B. Regulatory mechanisms involved in the control of HIV-1 gene expression. AIDS. 8:1994;S3-S17.
15. Giacca M., Gutierrez M.I., Menzo S., d'Adda di Fagnana F., Falaschi A. A human binding site for transcription factor USF/MLTF mimics the negative regulatory element of human immunodeficiency virus type 1. Virology. 186:1992;133-147.
16. Gilboa E., Smith C. Gene therapy for infectious diseases: the AIDS model. Trends Genet. 10:1994;139-144.
17. Gunnery S., Green S.R., Mathews M.B. Tat-responsive region RNA of human immunodeficiency virus type 1 stimulates in vivo and in vitro: relationship between structure and function. Proc. Natl. Acad. Sci. USA. 89:1992;11557-11561.
18. Harrich D., Hsu C., Race E., Gaynor R.B. Differential growth kinetics are exhibited by human immunodeficiency virus type 1 TAR mutants. J. Virol. 68:1994;5899-5910.
19. Harrich D., Mavankal G., Mette-Snider A., Gaynor R.B. Human immunodeficiency virus type 1 TAR element revertant viruses define RNA structures required for efficient viral gene expression and replication. J. Virol. 69:1995;4906-4913.
20. Heaphy S., Dingwall C., Ernberg I., Gail M.J., Green S.M., Karn J., Lowe A.D., Singh M., Skinner M.A. HIV-1 regulator of virion expression (Rev) binds to an RNA stem-loop structure located in the Rev response element region. Cell. 60:1990;685-693.
21. Helland D.E., Welles J.L., Caputo A., Haseltine W.A. Transcellular trans-activation by the human immunodeficiency virus type-1 tat protein. J. Virol. 65:1991;4547-4549.
22. Jeyapaul J., Seshamma T., Khan S. Synthetic HIV-1 Tat can dissociate HeLa nuclear protein-TAR RNA complexes in vitro: a novel Tat-nuclear protein interaction. Oncogene. 6:1991;1507-1513.
23. Klaver B., Berkhout B. Evolution of a disrupted TAR RNA hairpin structure in the HIV-1 virus. EMBO J. 13:1994;2650-2659.
24. Lisziewicz J., Sun D., Trapnell B., Thomson M., Chang H.-K., Ensoli B., Peng B. An autoregulated dual-function antitat gene for human immunodeficiency virus type 1 gene therapy. J. Virol. 69:1995;206-212.
25. Milligan J.F., Groebe D.R., Witherell G.W., Uhlenbeck O.C. Oligonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates. Nucleic Acids Res. 15:1987;8783-8798.
26. Rhim H., Rice A.P. TAR RNA binding properties and relative trans-activation activities of human immunodeficiency virus type 1 and 2 Tat proteins. J. Virol. 67:1993;1110-1121.
27. Rhim H., Rice A.P. RNAs selected in vitro by the HIV-2 Tat protein. J. Biomed. Sci. 4:1997;28-34.
28. Rosen C., Pavlakis G. Tat and rev: positive regulators of HIV gene expression. AIDS. 4:1990;499-509.
29. Rounseville M.P., Kumar A. Binding of a host cell nuclear protein to the stem region of human immunodeficiency virus type 1 trans-activation-responsive RNA. J. Virol. 66:1992;1688-1694.
30. Rounseville M.P., Lin H., Agbottah E., Shukla R.R., Rabson A.B., Kumar A. Inhibition of HIV-1 replication in viral mutants with altered TAR RNA stem structures. Virology. 216:1996;411-417.
31. Sullenger B.A., Gallardo H.F., Ungers G.E., Gilboa E. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 trans-activation. J. Virol. 65:1991;6811-6816.
32. Sutton J.A., Braddock M., Kingsman A.J., Kingsman S.M. Requirement for HIV-1 TAR sequences for Tat activation in rodent cells. Virology. 206:1995;690-694.
33. Szostak J.W. In vitro genetics. Trends Biochem. Sci. 17:1992;89-98.
34. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 249:1990;505-510.
35. Weeks K.M., Ampe C., Schltz S.C., Steitz T.A., Crothers D.M. Fragments of the HIV-1 Tat protein bind TAR RNA. Science. 249:1990;1281-1285.
36. Weeks K.M., Crothers D.M. RNA recognition by Tat-derived peptides: interaction in the major groove? Cell. 66:1991;577-588.
37. Zucher M. On finding all suboptimal foldings of an RNA molecule. Science. 244:1989;48-52.